Publication | Closed Access

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

MedicinePharmacologyPharmacotherapyAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyPhase 1Mtorc1/2 Inhibitor Pqr309Cancer ResearchOral Dual Pi3k